Better Therapeutics, Inc. BTTX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
| Older periods | Dec '22 | Mar '23 | Jun '23 | Sep '23 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.37 | 0.62 | 0.54 | 0.57 |
Net Debt/EBITDA |
0.11 | (1.04) | (1.29) | (1.71) | |
Debt/Assets |
64.86% | 113.52% | 122.48% | 133.44% | |
Debt/Equity |
(16.55) | (1.48) | (1.32) | (1.44) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.72 | 0.93 | 0.67 | 1.01 | |
Capex/Depreciation |
(0.50) | (0.69) | (0.63) | 0.08 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.28) | (0.39) | (0.18) | (0.15) | |
Cash per Share |
0.67 | 0.25 | 0.20 | 0.17 | |
Shareholders Equity per Share |
(0.04) | (0.41) | (0.35) | (0.26) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.04) | (0.41) | (0.35) | (0.26) | |
Free Cash Flow |
(6.70) | (9.24) | (5.59) | (5.88) | |
Working Capital |
4.95 | (5.20) | (6.45) | (5.59) | |
Capital Expenditures |
(0.36) | (0.52) | (0.50) | 0.07 | |
Net Current Asset Value |
(5.40) | (14.20) | (14.97) | (13.31) | |
| Other line items | |||||
Quick Ratio |
1.17 | 0.44 | 0.45 | 0.51 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.27) | (0.37) | (0.16) | (0.15) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | 0.00 | |
Average Payables |
2.28 | 1.62 | 2.04 | 1.78 | |
Average Assets |
36.95 | 26.55 | 24.35 | 19.47 | |
Average Common Equity |
17.91 | 8.80 | 3.63 | (1.34) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates